ONCAlert | 2018 ASCO Annual Meeting

How Cabozantinib is Being Used in Practice for Patients With RCC

Daniel James George, MD
Published Online: 5:42 PM, Fri April 28, 2017

Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.